COVID-19, Long Covid & Hyperbaric Oxygen

According to Harvard Health Publishing, Harvard Medical School “the hidden long-term cognitive effects of COVID-19 include neurological symptoms, impaired cognition, behaviour and psychological problems.

HBO has been shown to help ameliorate both acute and chronic inflammatory conditions by reducing pro-inflammatory cytokine release. Studies suggest that HBO has the ability to reverse hypoxia, reduce neuro-inflammation and improve tissue oxygenation. HBO is a potent virucidal, meaning it has the ability to kill COVID-19 viral cells. HBO has been shown to reduce coagulation factors to effectively address the increased clotting that COVID can create.

This case series describes COVID-19 symptoms persisting a mean of 60 days after onset among Italian patients previously discharged from COVID-19 hospitalization. https://pubmed.ncbi.nlm.nih.gov/32644129/

COVID-19 can result in prolonged illness, even among young adults without underlying chronic medical conditions. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392393/

The purpose of the current study is the evaluate the efficacy of HBOT in moderate-severe COVID-19 patients in a randomized controlled manner. https://clinicaltrials.gov/ct2/show/NCT04358926

Hyperbaric oxygen therapy (HBOT) treatment will be provided to patients as an adjunct to standard therapy for a cohort of 40 COVID19-positive patients with respiratory distress at NYU Winthrop Hospital. https://clinicaltrials.gov/ct2/show/NCT04332081

Our results demonstrate the safety of hyperbaric oxygen among COVID-19 patients and strongly suggests the need for a well-designed, multicenter randomized control trial https://pubmed.ncbi.nlm.nih.gov/32931666/

The aim of this study is to compare the effect of HBOT vs. Sham on post COVID-19 syndrome https://clinicaltrials.gov/ct2/show/NCT04647656